Literature DB >> 11605050

Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines.

K Nakayama1, K Miyazaki, A Kanzaki, M Fukumoto, Y Takebayashi.   

Abstract

One of the most important clinical problems in the treatment of human solid carcinoma is the intrinsic/acquired resistance. Cisplatin is a platinum compound that is one of the most effective agents in clinic. Copper-transporting P-type adenosine triphosphate (ATP7B) has been reported to be associated with cisplatin resistance by the experiment of transfection of full cDNA of ATP7B into KB3-1 lacking ATP7B. We examined the relationship between mRNA expression level of ATP7B and sensitivity to cisplatin in nine human ovarian carcinoma cell lines to extend these findings. mRNA expression level of ATP7B was significantly correlated with cisplatin-sensitivity in nine cell lines, raising the possibility that ATP7B could be a chemoresistance marker in some types of human solid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605050     DOI: 10.3892/or.8.6.1285

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  20 in total

1.  MKK4 acts as a potential tumor suppressor in ovarian cancer.

Authors:  Shamima Yeasmin; Kentaro Nakayama; Mohammed Tanjimur Rahman; Munmun Rahman; Masako Ishikawa; Atsuko Katagiri; Kouji Iida; Naomi Nakayama; Kohji Miyazaki
Journal:  Tumour Biol       Date:  2011-04-14

2.  Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas.

Authors:  Sultana Razia; Kentaro Nakayama; Kohei Nakamura; Tomoka Ishibashi; Masako Ishikawa; Toshiko Minamoto; Kouji Iida; Yoshiro Otsuki; Satoru Nakayama; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Exp Ther Med       Date:  2019-07-12       Impact factor: 2.447

Review 3.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

4.  Role of copper transporters in resistance to platinating agents.

Authors:  Cara A Rabik; Edward B Maryon; Kristen Kasza; John T Shafer; Catherine M Bartnik; M Eileen Dolan
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-08       Impact factor: 3.333

5.  ATP7B expression is associated with in vitro sensitivity to cisplatin in non-small cell lung cancer.

Authors:  Yoshimasa Inoue; Hozumi Matsumoto; Shunsuke Yamada; Kenji Kawai; Hiroshi Suemizu; Masatoshi Gika; Iwao Takanami; Masato Nakamura; Masayuki Iwazaki
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

6.  Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells.

Authors:  Milena Salerno; Dalila Yahia; Simplice Dzamitika; Elisabeth de Vries; Elene Pereira-Maia; Arlette Garnier-Suillerot
Journal:  J Biol Inorg Chem       Date:  2008-09-17       Impact factor: 3.358

7.  Cisplatin nephrotoxicity: molecular mechanisms.

Authors:  Marie H Hanigan; Prasad Devarajan
Journal:  Cancer Ther       Date:  2003

8.  ATP7B Binds Ruthenium(II) p-Cymene Half-Sandwich Complexes: Role of Steric Hindrance and Ru-I Coordination in Rescuing the Sequestration.

Authors:  Kallol Purkait; Arindam Mukherjee; Arnab Gupta
Journal:  Inorg Chem       Date:  2019-10-28       Impact factor: 5.165

Review 9.  Copper metabolism as a unique vulnerability in cancer.

Authors:  Vinit C Shanbhag; Nikita Gudekar; Kimberly Jasmer; Christos Papageorgiou; Kamal Singh; Michael J Petris
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-10-20       Impact factor: 4.739

10.  DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.

Authors:  Sanne R Martens-de Kemp; Simone U Dalm; Fiona M J Wijnolts; Arjen Brink; Richard J Honeywell; Godefridus J Peters; Boudewijn J M Braakhuis; Ruud H Brakenhoff
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.